Triptolide-loaded nanoparticles targeting breast cancer in vivo with reduced toxicity

Area of Science:

• Pharmacology
• Nanotechnology
• Oncology

Background:

• Triptolide (TP), derived from Tripterygium wilfordii, exhibits potent anti-cancer properties against various malignant tumors.
• However, TP's clinical application is hindered by poor water solubility and significant systemic toxicity.
• Developing effective drug delivery systems is crucial to overcome these limitations.

Purpose of the Study:

• To synthesize and evaluate nanoformulated Triptolide (TP) coated with hyaluronic acid (HA) for breast cancer treatment.
• To assess the efficacy and toxicity profile of HA-coated TP nanoparticles compared to free TP.
• To investigate the potential of this nanoformulation to improve drug delivery and therapeutic outcomes.

Main Methods:

• Synthesis of hyaluronic acid (HA)-coated Triptolide (TP) nanoparticles.
• In vitro and in vivo studies to evaluate drug uptake, anti-tumor efficacy, and systemic toxicity.
• Comparison of nanoformulated TP with free TP in preclinical breast cancer models.

Main Results:

• Nanoformulated TP demonstrated facilitated drug uptake into tumor tissues.
• The HA-coated TP nanoparticles significantly enhanced anti-cancer efficacy compared to free TP.
• Systemic toxicity was markedly reduced with the nanoformulated TP, improving the therapeutic index.

Conclusions:

• Hyaluronic acid (HA)-coated nanoformulated Triptolide (TP) represents a promising strategy to improve the therapeutic potential of TP for breast cancer.
• This approach enhances anti-tumor activity while mitigating systemic toxicity, paving the way for potential clinical translation.
• Targeted drug delivery via nanotechnology offers a viable solution for overcoming the challenges associated with potent chemotherapeutic agents like TP.